title: Systemic chemotherapy.
abstract: The main use of systemic chemotherapy in metastatic melanoma remains palliative. Dacarbazine (dimethyl-1-triazeno imidazole-4-carboxamide [DTIC]) is the standard chemotherapy agent for advanced disease. The combination chemotherapy and biochemotherapy regimens have achieved higher response rates, but have not led to durable remission or improved survival. The field of systemic therapy remains in need of a more effective and less toxic treatment strategy.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
authors.forename: V M
authors.initials: VM
authors.lastname: Klimek
authors.forename: J D
authors.initials: JD
authors.lastname: Wolchok
authors.forename: P B
authors.initials: PB
authors.lastname: Chapman
authors.forename: A N
authors.initials: AN
authors.lastname: Houghton
authors.forename: W J
authors.initials: WJ
authors.lastname: Hwu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D020360:Neoadjuvant Therapy; D010166:Palliative Care; D012074:Remission Induction; D012878:Skin Neoplasms / Q000473:pathology*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D003606:Dacarbazine